PCN245 Examining Longitudinal Practice Patterns in the use of ANTI-PD-1 and ANTI-PD-L1 Inhibitors as First-Line Therapy in Non-Small Cell Lung Cancer Patients in the US von Veluswamy, R., Barnes, G., Strauss, R., Harrough, D., Tang, B.

Volltext

Safety and efficacy of retreating follicular non-Hodgkin’s lymphoma (NHL) with 90 Y ibritumomab tiuxetan von Shah, J., Harrough, D., Saville, W., Mueh, J., Lister, J., Jasthy, S., Gregory, M., McKay, C., Krumdieck, R., Forero, A.

Volltext

Low frequency of altered biodistribution detected by Indium-111 imaging prior to yttrium-90 ibritumomab tiuxetan radioimmunotherapy: Imaging registry results von Conti, P. S., White, C. A., Pieslor, P., Menendez, G., Harrough, V. D., Matso, D., Aussie, J., Ryskamp, T., Foster, P. A.

Volltext